MINIMAL RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA WITH MUTATED NPM1: PROSPECTICAL EVALUATION AND MRD DIRECTED THERAPY

MLA

Guolo, F., et al. Minimal Residual Disease Assessment in Acute Myeloid Leukemia with Mutated Npm1: Prospectical Evaluation and Mrd Directed Therapy. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..58b3dc82aa26468162f20a1b481272ac&authtype=sso&custid=ns315887. Accessed 30 Oct. 2024.

APA

Guolo, F., Paola Minetto, Clavio, M., Di Grazia, C., Colombo, N., Raiola, A. M., Guardo, D., Coviello, E., Ballerini, F., Miglino, M., Angelucci, E., Bacigalupo, A., Lemoli, R. M., & Gobbi, M. (n.d.). Minimal Residual Disease Assessment in Acute Myeloid Leukemia with Mutated Npm1: Prospectical Evaluation and Mrd Directed Therapy.

Chicago

Guolo, F., Paola Minetto, M. Clavio, C. Di Grazia, N. Colombo, A. M. Raiola, D. Guardo, et al. 2024. “Minimal Residual Disease Assessment in Acute Myeloid Leukemia with Mutated Npm1: Prospectical Evaluation and Mrd Directed Therapy.” Accessed October 30. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..58b3dc82aa26468162f20a1b481272ac&authtype=sso&custid=ns315887.